Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial

Imran B Chaudhry, Nusrat Husain, Mohammad O Husain, Jamie Hallak, Richard Drake, Ajmal Kazmi, Raza ur Rahman, Mohammad M Hamirani, Tayyaba Kiran, Nasir Mehmood, John Stirling, Graham Dunn, Bill Deakin, Imran B Chaudhry, Nusrat Husain, Mohammad O Husain, Jamie Hallak, Richard Drake, Ajmal Kazmi, Raza ur Rahman, Mohammad M Hamirani, Tayyaba Kiran, Nasir Mehmood, John Stirling, Graham Dunn, Bill Deakin

Abstract

Background: Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either. There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that ondansetron is effective as an adjunct drug in improving the symptoms of schizophrenia.

Methods/design: This is a two center, six-month, double-blind placebo controlled, factorial design study of ondansetron and/or simvastatin added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. This will be a 2 × 2 design, with 54 patients in each cell, giving a total of 216 patients over three years. There will be a screening, a randomization and seven follow-up visits. Full clinical and neurocognitive assessments will be carried out at baseline (randomization), 14 weeks and at 26 weeks, while the positive and negative syndrome scale (PANSS), pill count and side effects checklist will be carried out at every visit. Simvastatin will be started at 20 mg once daily (OD), this will be increased to 40 mg after four weeks. Ondansetron will be administered in an 8 mg dose.

Discussion: Anti-inflammatory treatments have been shown to have some beneficial effects in schizophrenia. Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared to treatment as usual. The aim of this study is to establish the degree of improvement in negative symptoms with the addition of ondansetron and/or simvastatin to treatment as usual.

Trial registration: [corrected] ClinicalTrials.gov NCT01602029.

References

    1. Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, Mawrin C, Schmitt A, Jordan W, Müller UJ, Bernstein HG, Bogerts B, Steiner J. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun. 2012;26:1273–1279. doi: 10.1016/j.bbi.2012.08.005.
    1. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63:801–808. doi: 10.1016/j.biopsych.2007.09.024.
    1. Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009;14:1069–1071. doi: 10.1038/mp.2009.52.
    1. Mansur RB, Zugman A, Asevedo EM, da Cunha GR, Bressan RA, Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci. 2012;66:247–260. doi: 10.1111/j.1440-1819.2012.02354.x.
    1. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165–171. doi: 10.1001/archpsyc.58.2.165.
    1. Leeson VC, Barnes TR, Hutton SB, Ron MA, Joyce EM. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009;107:55–60. doi: 10.1016/j.schres.2008.08.014.
    1. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs. 2010;11:31–42.
    1. Chaudhry IB, Husain N, Hallak J, Minhas FA, Dursun S, Richardson P, Stirling J, Riaz R, Chaves C, Deakin JF. Preventing clinical deterioration in first episode psychosis: potential role of minocycline in neuroprotection [abstract] Biol Psychiatry. 2009;64:s91.
    1. Müller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des. 2008;14:1452–1465. doi: 10.2174/138161208784480243.
    1. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149:267–271. doi: 10.1016/j.psychres.2006.07.011.
    1. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322:816–821. doi: 10.1056/NEJM199003223221205.
    1. Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206–212. doi: 10.1016/j.schres.2008.08.004.
    1. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull. 2005;65:291–295. doi: 10.1016/j.brainresbull.2003.09.022.
    1. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006;88:102–110. doi: 10.1016/j.schres.2006.07.010.
    1. Fiebich BL, Akundi RS, Lieb K, Candelario-Jalil E, Gmeiner D, Haus U, Müller W, Stratz T, Muñoz E. Anti-inflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol Suppl. 2004;119:28–32.
    1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4th Edition, Text Revision) Washington, DC: American Psychiatric Association; 2000.
    1. Birchwood M. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853–859. doi: 10.1192/bjp.157.6.853.
    1. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–398. doi: 10.1093/schbul/10.3.388.
    1. Yusufi BZ, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes TR. Inter-rater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS). In Abstracts of the XX International Congress on Schizophrenia Research, April 2 – April 6, 2005, Savannah, Georgia. Schizophr Bull. 2005;31:574.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj